Newsbenzinga
Beam Therapeutics Targets Accelerated FDA Approval for Base-Editing Treatment
· Published
Article summary
Beam Therapeutics reported positive Phase 1/2 trial data for BEAM-302 to treat AATD, targeting accelerated FDA approval with a 60 mg dose.
An excerpt from the original article.
Comments —
Loading comments…